MBD3/NuRD Facilitates Induction of Pluripotency in a Context-Dependent Manner
By knocking out MBD3, an essential scaffold subunit of the Nucleosome Remodeling and Deacetylase (NuRD) complex, at different time points in reprogramming, researchers found that efficient formation of reprogramming intermediates and induced pluripotent stem cells from neural stem cells requires NuRD activity. [Cell Stem Cell]
Full Article|Graphical Abstract
Tet Oxidizes Thymine to 5-Hydroxymethyluracil in Mouse Embryonic Stem Cell DNA
Scientists synthesized isotopologs of all major oxidized pyrimidine and purine bases and performed quantitative MS to show that ten eleven translocation (Tet)-induced oxidation is not limited to 5-methylcytosine but that thymine is also a substrate that gives 5-hydroxymethyluracil in mouse embryonic stem cells. [Nat Chem Biol]
Abstract|Press Release
Induced Pluripotent Stem Cells for Modeling of Pediatric Neurological Disorders
The authors provide an overview of various gene delivery systems for generating induced pluripotent stem cells, the current state of modeling early-onset neurological disorders and the ultimate application of these in-vitro models in cell therapy through the correction of disease-specific mutations. [Biotechnol J]
Abstract
Visit our reviews page to see a complete list of reviews in the ESC & iPSC research field.
INDUSTRY NEWS
Taxus Cardium’s Excellagen® Selected for Use with Stem Cells in EU-Funded Human Clinical Study
Taxus Cardium Pharmaceuticals Group Inc. announced that the company’s Excellagen® flowable dermal matrix in combination with Orbsen Therapeutics’ mesenchymal stromal stem cell therapy Cyndacel-M™ has been selected for clinical evaluation in a Phase Ib safety study for the potential treatment of chronic diabetic wounds to be funded by the European Union under EU Framework 7. [Taxus Cardium Pharmaceuticals Group Inc.] Press Release
Researchers Slam Transparency ‘U-Turn’ at E.U. Medicines Agency
Researchers are worried that the European Medicines Agency is backpedaling on its pledge to open clinical trials data to public scrutiny. Draft documents detailing how the agency plans to make such data available contains small print that may severely limit access and that constitutes a turnaround from earlier promises for openness, academics say. [ScienceInsider]
Editorial
NIH to Require Sex-Reporting in Preclinical Studies
The US National Institutes of Health (NIH) will require grant applicants to report the sex of animals and cells used in preclinical studies. The shift could help to reveal differences in the ways that diseases affect males and females. [Nature News]
Editorial
No Patent for Dolly the Cloned Sheep, Court Rules, Adding to Industry Jitters
Dolly the sheep enjoyed a brief and highly publicized life as the first mammal cloned from an adult cell before succumbing to lung disease in 2003 at age 6. But an attempt to patent Dolly, and lay commercial claim to animals produced by cloning, survived much longer. But that nearly 10-year-long saga also appears to have ended last week when a U.S. federal appeals court ruled against giving a patent to Dolly’s creators. [ScienceInsider]
Editorial
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in ESC & iPSC News? Click here to submit!
Comments or suggestions? Submit your feedback here.
